Details of the Drug Combination

General Information of Drug Combination (ID: DC5N9CK)

Drug Combination Name
Arfolitixorin Topetecan
Indication
Disease Entry Status REF
Papillary renal cell carcinoma Investigative [1]
Component Drugs Arfolitixorin   DMIXMYK Topetecan   DMAE6LK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: ACHN
Zero Interaction Potency (ZIP) Score: 0.03
Bliss Independence Score: 1.26
Loewe Additivity Score: 1.14
LHighest Single Agent (HSA) Score: 3.4

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Arfolitixorin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Indication(s) of Topetecan
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [3]
Topetecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Anaplastic large cell lymphoma DCCPRC4 SR Investigative [1]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).